NO20045070L - Fremgangsmate for a frembringe en 2-18F-fluor-2-deoksy-D-glukose(18F-FDG)-losning - Google Patents

Fremgangsmate for a frembringe en 2-18F-fluor-2-deoksy-D-glukose(18F-FDG)-losning

Info

Publication number
NO20045070L
NO20045070L NO20045070A NO20045070A NO20045070L NO 20045070 L NO20045070 L NO 20045070L NO 20045070 A NO20045070 A NO 20045070A NO 20045070 A NO20045070 A NO 20045070A NO 20045070 L NO20045070 L NO 20045070L
Authority
NO
Norway
Prior art keywords
fdg
deoxy
glucose
solution
fluor
Prior art date
Application number
NO20045070A
Other languages
English (en)
Other versions
NO329160B1 (no
Inventor
Petrus Simon Kruijer
Hector Humberto Knight
Original Assignee
Mallinckrodt Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt Inc filed Critical Mallinckrodt Inc
Publication of NO20045070L publication Critical patent/NO20045070L/no
Publication of NO329160B1 publication Critical patent/NO329160B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/121—Solutions, i.e. homogeneous liquid formulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B63/00—Purification; Separation; Stabilisation; Use of additives
    • C07B63/04—Use of additives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20045070A 2002-04-24 2004-11-22 Fremgangsmate for a frembringe en 2-18F-fluor-2-deoksy-D-glukose(18F-FDG)-losning NO329160B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02076638A EP1356827A1 (en) 2002-04-24 2002-04-24 Method for obtaining a 2-18F-fluor-2-deoxy-D-glucose (18F-FDG)-solution
PCT/US2003/012603 WO2003090789A1 (en) 2002-04-24 2003-04-23 Method for obtaining a 2-18f-fluor-2-deoxy-d-glucose (18f-fdg) - solution

Publications (2)

Publication Number Publication Date
NO20045070L true NO20045070L (no) 2004-11-22
NO329160B1 NO329160B1 (no) 2010-08-30

Family

ID=28685968

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20045070A NO329160B1 (no) 2002-04-24 2004-11-22 Fremgangsmate for a frembringe en 2-18F-fluor-2-deoksy-D-glukose(18F-FDG)-losning

Country Status (13)

Country Link
US (1) US8182788B2 (no)
EP (2) EP1356827A1 (no)
JP (2) JP5132869B2 (no)
KR (1) KR20050005456A (no)
CN (1) CN1323724C (no)
AT (1) ATE422903T1 (no)
AU (1) AU2003225124B2 (no)
CA (1) CA2483181C (no)
DE (1) DE60326220D1 (no)
IL (2) IL164805A0 (no)
NO (1) NO329160B1 (no)
PL (1) PL371682A1 (no)
WO (1) WO2003090789A1 (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0422004D0 (en) 2004-10-05 2004-11-03 Amersham Plc Method of deprotection
JP5112062B2 (ja) * 2005-06-14 2013-01-09 日本メジフィジックス株式会社 放射性画像診断剤
TW200803903A (en) * 2006-04-28 2008-01-16 Nihon Mediphysics Co Ltd Novel compound having affinity to amyloid
EP2368580A1 (en) * 2006-06-21 2011-09-28 Ge Healthcare As Stabilisation of fluorothymidine precursors
CA2655826A1 (en) * 2006-06-21 2007-12-27 Nihon Medi-Physics Co., Ltd. Novel compound having affinity for amyloid
US20100056826A1 (en) * 2006-11-09 2010-03-04 Nihon Medi-Physicis Co., Ltd. Radioactive diagnostic imaging agent
JP5159636B2 (ja) * 2006-12-21 2013-03-06 日本メジフィジックス株式会社 放射性画像診断剤
KR101485445B1 (ko) 2007-02-13 2015-01-22 니혼 메디피직스 가부시키가이샤 방사성 화상진단제의 제조 방법
KR20100091965A (ko) * 2007-10-24 2010-08-19 니혼 메디피직스 가부시키가이샤 신규 아밀로이드 친화성 화합물
WO2009057577A1 (ja) * 2007-10-30 2009-05-07 Nihon Medi-Physics Co., Ltd. 新規アミロイド親和性化合物の使用及び製造方法
EP2218463A1 (en) * 2007-10-30 2010-08-18 Nihon Medi-Physics Co., Ltd. Use of novel compound having affinity for amyloid, and process for production of the same
EP2214722A1 (en) * 2007-11-07 2010-08-11 GE Healthcare BV Stabilization of radiopharmaceuticals
PT2419096T (pt) 2009-04-15 2020-02-19 Lantheus Medical Imaging Inc Estabilização de composições radiofarmacêuticas utilizando ácido ascórbico
EP2603243B1 (en) * 2010-08-13 2020-02-19 Siemens Medical Solutions USA, Inc. Formulation, apparatus and method for stabilizing radiopharmaceuticals
US11504430B2 (en) 2010-12-29 2022-11-22 Ge Healthcare Limited Eluent solution
US20130004414A1 (en) * 2011-06-30 2013-01-03 General Electric Company Devices and methods for reducing radiolysis of radioisotopes
US20130005958A1 (en) * 2011-06-30 2013-01-03 General Electric Company Devices and methods for reducing radiolysis of radioisotopes
GB201411569D0 (en) 2014-06-30 2014-08-13 Ge Healthcare Ltd Novel formulation and method of synthesis
GB2509476B (en) * 2011-12-21 2018-08-08 Ge Healthcare Ltd Ip 18F - Fluciclovine compositions in citrate buffers
US11534494B2 (en) 2011-12-21 2022-12-27 Ge Healthcare Limited Formulation and method of synthesis
GB201202420D0 (en) * 2012-02-13 2012-03-28 Ge Healthcare Ltd Radiotracer compositions
US10695450B2 (en) 2016-07-26 2020-06-30 Laboratoires Cyclopharma Synthesis of a radioactive agent composition
FR3054445B1 (fr) * 2016-07-26 2019-07-05 Laboratoires Cyclopharma Synthese d'une composition d'agent radioactif
GB202005282D0 (en) * 2020-04-09 2020-05-27 Blue Earth Diagnostics Ltd Pharmaceutical Formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4707353A (en) * 1982-12-08 1987-11-17 Mallinckrodt, Inc. Radiographic imaging agents
SE9002117L (sv) * 1990-06-14 1991-08-26 Nils Elander Mikrovaagsanordning foer behandling av precessvaetskor
DK0538402T3 (da) 1990-07-06 2006-07-10 Mallinckrodt Inc Fremgangsmåde til fremstilling af en oplösning af et radioaktivt rhenium-kompleks
JPH0797340A (ja) * 1993-06-03 1995-04-11 Terumo Corp Ｍｒｉ造影剤組成物
BE1010280A3 (fr) 1996-05-02 1998-05-05 Coincidence S A Procede et dispositif de synthese de 2-[18f] fluoro-2-deoxy-d-glucose.
CN1239895A (zh) * 1996-10-07 1999-12-29 杜邦药品公司 用于对感染和炎症部位造影的放射药物

Also Published As

Publication number Publication date
AU2003225124A1 (en) 2003-11-10
ATE422903T1 (de) 2009-03-15
KR20050005456A (ko) 2005-01-13
EP1496946A1 (en) 2005-01-19
DE60326220D1 (de) 2009-04-02
JP2010248244A (ja) 2010-11-04
US8182788B2 (en) 2012-05-22
PL371682A1 (en) 2005-06-27
CA2483181C (en) 2011-06-28
AU2003225124B2 (en) 2007-06-14
JP5132869B2 (ja) 2013-01-30
JP2006500319A (ja) 2006-01-05
IL164805A0 (en) 2005-12-18
EP1356827A1 (en) 2003-10-29
CA2483181A1 (en) 2003-11-06
EP1496946B1 (en) 2009-02-18
US20050175536A1 (en) 2005-08-11
IL164805A (en) 2009-06-15
CN1323724C (zh) 2007-07-04
WO2003090789A1 (en) 2003-11-06
NO329160B1 (no) 2010-08-30
CN1646175A (zh) 2005-07-27

Similar Documents

Publication Publication Date Title
NO20045070L (no) Fremgangsmate for a frembringe en 2-18F-fluor-2-deoksy-D-glukose(18F-FDG)-losning
ES2246227T8 (es) Moléculas de ácido nucleico que codifican alternansacarasa
EP3537217A3 (en) Positive resist composition, resin used for the positive resist composition, compound used for synthesis of the resin and pattern forming method using the positive resist composition
BRPI0409969A (pt) composto, composição farmacêutica, uso de um composto, e, processo para preparar um composto
ATE249420T1 (de) Herstellung von iodixanol
BR0314133A (pt) Métodos para a preparação, isolamento e purificação de epotilona b e raios x de estruturas de cristal de epotilona b
NO20054615L (no) Mikrobolgemetode
ATE496098T1 (de) Strahlenhärtende lacksysteme
NO20054169D0 (no) 3-(1-[3-(1,3-benzotiazol-6-yl) propylkarbamoyl]sykloalkyl]propansyrederivater som NEP-inhibitorer.
WO2001082785A3 (en) An optical monitor for sudden infant death syndrome
DE60028600D1 (de) Uv-härtbare zusammensetzungen
ATE506346T1 (de) Verfahren zur herstellung von (z)-1-phenyl-1-(n,n-diethylaminocarbonyl)idomet ylcyclopropan
CA2585802A1 (en) Industrial process for the preparation of 17-hydroxy-6.beta.,7.beta.;15.beta.,16.beta.-bismethylene-3-oxo-17.alpha.pregn-4-ene-21-carboxylic acid.gamma.-lactone and key-intermediates for this process
WO2002019108A8 (en) Method for providing bitwise constraints for test generation
ATE461283T1 (de) Neue vollständige genomische rna des japanenzephalitis-virus, infektiöse jev cdna daraus und deren verwendung
UA86775C2 (ru) Способ очистки раствора альфа-1-антитрипсина
BRPI0409069A (pt) compostos quìmicos
ES2103623T3 (es) Procedimiento de obtencion de zeolitas que contienen titanio.
WO2006080043A3 (en) Organic compounds useful for the treatment of alzheimer's disease, their use and method of preparation
ATE533086T1 (de) Lichtempfindliche zusammensetzung und verfahren zur strukturformung damit
BRPI0407448A (pt) Processo quìmico
ES2349654T8 (es) Purificación de compuestos de beta-lactama.
EP1491951A3 (en) Positive-working resist composition
ATE278044T1 (de) Goldlegierung und verfahren zu deren herstellung
ATE544738T1 (de) Verfahren zur herstellung von ä18füfluoralkylhalogeniden

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees